Lindynette 30

Ethinylestradiol, the active ingredient in Lindynette 30, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 0.075 mg gestodene oral tablet for oral use. It is a hormonal contraceptive indicated for the prevention of pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus and endometrial lining.

GNH USA supplies Lindynette 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Lindynette 30 is a combined oral contraceptive that acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy and can also be used for related hormonal conditions.

Contraception: provides reliable prevention of pregnancy in women of childbearing potential. Acne vulgaris: helps reduce inflammatory lesions and improve skin appearance. Menstrual disorders: can regulate cycle length and reduce dysmenorrhea.

Lindynette 30 may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain or fluid retention - Mood changes - Breakthrough or spotting bleeding

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Hypertension or worsening of existing hypertension - Hepatic adenoma or other liver disorders - Gallbladder disease (cholestasis, gallstones) - Severe allergic reactions (anaphylaxis, angioedema)

Before prescribing Lindynette 30, clinicians should evaluate individual risk factors and contraindications. - Contraindications: known thrombogenic disorders, estrogen‑dependent tumors, active liver disease, pregnancy, breastfeeding. - Smoking: avoid use in women over 35 who smoke due to increased cardiovascular risk. - Cardiovascular risk: assess history of hypertension, stroke, or myocardial infarction before initiation. - Drug interactions: review concomitant medications that may induce hepatic enzymes or affect hormone levels. - Regular monitoring: check blood pressure and lipid profile periodically, especially in high‑risk patients. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and light.

Lindynette 30 can interact with several medicines that alter hormone metabolism or increase thrombotic risk.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy. - Rifampicin: decreases hormone levels, increasing risk of unintended pregnancy. - Protease inhibitors (e.g., ritonavir): may raise hormone concentrations and heighten side‑effect risk.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone levels. - St. John’s wort: may lower contraceptive effectiveness. - Certain antibiotics (e.g., tetracycline, metronidazole): generally minimal effect but require monitoring for breakthrough bleeding.